. The point prevalence, however, is only 5 per 100,000 people because of the very poor prognosis.
To date, only a small number of non-genetic risk factors for ALS have been reliably confirmed. Age is one such risk factor, although whether the risk is reduced in very elderly individuals (>85 years) is not clear 5 . Several studies have also indicated that male sex is a nongenetic risk factor for ALS, as patient populations have a 3:2 male:female ratio. This sex difference, however, does not hold true for all populations, and might depend on the age structure of the studied group, as men predominate in younger groups of patients [6] [7] [8] [9] . Here, we outline previous and current efforts to characterize genes that are associated with ALS, describe current knowledge about the genetic architecture of ALS -including the relevance of family history -and the probable nature of future gene discoveries, and explore how our understanding of ALS genetics affects present and future clinical decisions.
Genetics and sporadic ALS
A substantial proportion of patients with ALS report a positive family history of ALS, FTD or both, with figures ranging from 5-20% depending on the definition of familial ALS 10 . Familial ALS obviously has a genetic component, but whether apparently sporadic ALS has a genetic basis is not clear. Twin and other family studies have shown that the heritability of apparently sporadic ALS is ~60%, suggesting that a substantial genetic contribution is available for discovery, even in patients with no family history [11] [12] [13] . The ability to easily differentiate between familial and apparently sporadic ALS would aid genetic counselling and inform suitable research strategies for gene discovery; the boundary between the two, however, is Abstract | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. The disease leads to relentlessly progressive weakness of voluntary muscles, with death typically resulting from diaphragmatic failure within 2-5 years.
Since the discovery of mutations in SOD1, which account for ~2% of ALS cases, increasing efforts have been made to understand the genetic component of ALS risk, with the expectation that this insight will not only aid diagnosis and classification, but also guide personalized treatment and reveal the mechanisms that cause motor neuron death. In this Review, we outline previous and current efforts to characterize genes that are associated with ALS, describe current knowledge about the genetic architecture of ALS -including the relevance of family history -and the probable nature of future gene discoveries, and explore how our understanding of ALS genetics affects present and future clinical decisions. We observe that many gene variants associated with ALS have effect sizes between those of mutations that greatly increase risk and those of common variants that have a small effect on risk, and combine this observation with insights from next-generation sequencing to explore the implications for genetic counselling. not clear-cut, and the definition of familial ALS varies between physicians 14 . Furthermore, the probability of obtaining a positive family history for ALS depends on family size, even when a patient expresses a single gene variant that is associated with a large increase in the risk of ALS 15 . This probability drops if the identified disease gene variant contributes only moderately to ALS risk or increases the risk of other conditions in addition to ALS 16 . Mutations associated with familial ALS will, therefore, sometimes be identified in individuals with apparently sporadic ALS, an observation that has been confirmed in multiple studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The corollary is that even apparently sporadic ALS can be a consequence of a few gene variants that each independently confer a moderate risk, rather than the cumulative effect of multiple common gene variants that independently contribute only marginally to disease risk.
Genetic architecture of ALS
Family-based studies have been highly successful in identifying genes associated with ALS. In the past, familial studies relied on a method called linkage to home in on the disease-related genes. Advances in genetics, however, have made it possible to sequence the entire genome (wholegenome sequencing) or focus on the protein-coding portion of the genome where disease-related gene variations are likely to be found (whole-exome sequencing). Nevertheless, whole-genome and whole-exome sequencing will miss some forms of genetic variation. The combination of sequencing with linkage is an excellent method for identifying ALS-associated genes in families 29, 30 , but is still imperfect: even the most frequent cause of ALS -a hexanucleotide repeat (GGGGCC) expansion to hundreds or thousands of repeats in an intron of the C9orf72 gene -is not detectable by sequencing, because large and repetitive sequences are missed by the tools currently used. This shortcoming emphasizes the importance of using statistical techniques, family studies and other methods in addition to whole-genome sequencing.
In sporadic ALS, a widely used method for gene discovery is to search for associations between genetic variants and disease status in case-control studies. Genome-wide association studies (GWAS) of common variants have identified seven replicable ALS risk loci 26, 27, [31] [32] [33] . This method of gene discovery is based on the 'common disease-common variant' hypothesis, under which sporadic ALS is assumed to result from the cumulative effects of multiple common genetic variants. Therefore, considering ALS to be a common disease in this context might reveal the genetic architecture -multiple small contributions to risk or a few large contributions to risk.
Conditions such as schizophrenia, obesity or hypertension, for which the lifetime risk is ~1% or more, are sufficiently common for the common disease-common variant hypothesis to apply. Rare diseases with a genetic basis, on the other hand, are often caused by large-effect mutations in a single gene, and the lifetime risk of these diseases is a tiny fraction of a percent -Huntington disease is an example of such a condition. ALS lies somewhere between these two extremes, suggesting that it might have an intermediate genetic architecture. A review of lists of genetic risk factors for ALS [34] [35] [36] , focusing on those in the manually curated Online Mendelian Inheritance in Man (OMIM) database 37 (see Supplementary information S1 (table)), combined with examination of genes identified from GWAS 38 (TABLE 1) , provides some insights into the likely genetic architecture of ALS.
As for other neurodegenerative diseases, studies in ALS have identified one highly significant genetic association, in this case with genetic variation on chromosome 9 (REFS 31,32). Despite the strength of this association, its detection required sample sizes in the thousands, and its replication required a further increase in sample size. The association signal corresponded to the genetic location of a signal identified in families with inherited forms of ALS [39] [40] [41] [42] [43] [44] [45] . We now know that the associations in both contexts are with the aforementioned hexa nucleotide repeat expansion in the C9orf72 gene 24, 46 . The reason this expansion is detectable with both casecontrol association studies and family-based studies is that it moderately increases the risk of ALS and/or FTD -its effect lies between that of a rare gene variant that almost inevitably leads to disease and that of common genetic variation that only marginally increases disease risk (FIG. 1) . Consequently, the hexanucleotide expansion is responsible for up to 10% of cases of apparently sporadic ALS in some populations, and for about 30% of cases of familial ALS.
Associations with ALS have been identified and replicated for common gene variants that increase the risk of disease by only a small amount 18,47 (TABLE 1) . A wellreplicated risk factor for ALS is intermediate expansion of the CAG trinucleotide repeat in the ataxin-2 (ATXN2) gene, although larger repeats are known to cause spinocerebellar ataxia 48 . Variants in elongator complex protein 3 (ELP3) have been associated with ALS; no replication studies have been conducted, as the dinucleotide (CA) repeat is not detected by methods used in GWAS, but functional work supports the findings 49 . Similarly, survival motor neuron protein (SMN1) copy number variation 50 , as well as insertion or deletion mutations in the neurofilament heavy polypeptide (NEFH) gene, are considered to be risk factors for ALS 51 ( Single nucleotide variations account for 8.5% of the heritability of ALS, compared with 21% for schizophrenia. This difference suggests that rare variation, structural variants (such as large deletions or inversions), and repeat sequences that are not detected by current high-throughput techniques must account for much of the heritability of ALS 27, 52 . A large GWAS of ALS has provided support for this view, as it revealed that low-frequency variants make a larger than expected contribution to genetic susceptibility to ALS
Sequencing as a gene-finding strategy As low-frequency variation seems to have a large role in the genetic architecture of ALS, including apparently sporadic ALS, looking for such variants is important. In the absence of a family history of ALS, a case-control design, in which patient samples are compared with samples from people without ALS, is the simplest approach for gene discovery, but requires the ability to sequence the whole genome to identify the rare variation. Whole-genome sequencing is now feasible, but interpretation of the findings is not straightforward
. Difficulties arise because not all protein-changing mutations that are found in patients but not in controls indicate pathogenicity: among the general population, each person has, on average, ten major protein-truncating or protein-extending mutations without obvious disease effects 53 . Problems also arise if the disease causing mutations are rare, as the numbers available for statistical testing are small. Furthermore, rare variants are likely to be specific to certain populations, making replication studies difficult and leading to uncertainty regarding the statistical confidence of a relationship between a variant and disease. Some of these issues could be addressed by postmortem studies to determine whether the protein encoded by a putative ALS-associated gene is present in pathological inclusions or aggregates, but this approach is only possible if postmortem material is available, and is only informative if the protein is detected 54 . The challenges involved in identification of diseasecausing mutations in ALS are illustrated by the discovery of superoxide dismutase 1 (SOD1) mutations.
The initial linkage-based studies showed a diseaseassociated locus on chromosome 21, which led to the identification of the Ala5Val substitution mutation in SOD1 as a causative variant in ALS 55, 56 . Other SOD1 mutations were subsequently identified on the basis of linkage and/or functional evidence 16, 57, 58 . The discovery of SOD1 mutations as pathogenic led to widespread sequencing of the gene in families with a history of ALS and individuals with apparently sporadic ALS. The result was the discovery of over 130 mutations in SOD1, which encodes a protein of only 153 amino acids 36 . The identification of protein-changing mutations in known ALS-associated genes does not necessarily mean that the mutation is causative, and functional evidence or evidence of familial segregation is often lacking or limited 16, 59 . A similar problem arises with the largescale sequencing of genomes: identification of a rare genetic variant in a patient with ALS cannot, on its own, be regarded as evidence that the variant is pathogenic, even if it occurs in a gene that is known to be associated with ALS. Moreover, as the variant is rare by definition, statistical support cannot be provided for the association with ALS. Bioinformatics methods are also ineffective for predicting whether a rare variant is detrimental; for example, many protein-coding variants entered into in the Exome Aggregation Consortium (ExAC) database are predicted to have detrimental effects, despite being found in the general population 60 .
Interpreting the impact of a mutation is even more difficult if the mutation resides in the 99% of the genome that does not encode proteins. Progress has been made in our efforts to understand the noncoding component of the genome 61 , but we do not completely understand how the nuclear and cellular machinery interprets the sequence. We are also beginning to understand a number of confounders, such as the 3D conformation of the genome 62 , the effects of genome structure on transcription 63 , and somatic mosaicism 64 . One response to these problems is collaboration on a truly global scale. This strategy increases the number of patients in any given analysis, thereby improving the chances of rare variants being observed in multiple individuals and enabling statistical analysis of their associations with ALS. Furthermore, large collaborative projects could identify particular domains of proteins in which mutations are clustered, allowing functional studies to determine the pathogenicity of lesions in a specific region of a protein. If functional interpretations are not possible, burden testing can be used to determine whether an identified mutation is pathogenic. Burden testing involves conducting a simple count of rare variants per gene in both cases and controls; a statistically significant excess of rare variants in the disease group can support an argument for a pathological role of the relevant gene. Project MinE is an ongoing international whole-genome sequencing consortium that is funded by crowdsourcing. This collaborative effort is on target to achieve its goal of collecting the whole-genome sequences of 15,000 patients with ALS and 7,500 participants from the general population. Although the scale of Project MinE is unprecedented, the investigators still need to expand the study population to include more controls, so as to increase the reliability of the results.
Development of ALS treatments
Family-based whole-exome and whole-genome sequencing, and large-scale genome-wide case-control association studies, have uncovered a number of novel ALS risk variants in various genes, and have highlighted potential molecular pathways that might be involved in pathogenesis and could, therefore, be therapeutic targets (see Supplementary information S1 ( 28 . TBK1 is also known to be involved in autophagy, especially autophagosome maturation, and in the clearance of pathological aggregates through the proteasome. Other proteins implicated in ALS and also involved in the proteasomal pathway include protein unc-13 homologue A (encoded by UNC13A), ataxin-2, ubiquilin-2, sequestosome-1, and sterile alpha and TIR motif-containing protein 1. Through the NF-κB pathway, TBK1 also has a role in innate immunity signalling, which is related to neuroinflammation and could increase the risk of ALS and the rate of disease progression 65 . Genetic linkage study A family study design based on the phenomenon whereby specific alleles are transmitted from affected parents to affected offspring more often than expected by chance. Linkage studies are typically good for identifying variants that are sufficient to cause disease alone, but not so good at identifying variants that marginally increase risk.
Candidate gene study
Comparison between cases and controls of variation in one or more genes, where the genes are selected on the basis of a biologically plausible hypothesis of disease causation.
Genome-wide association studies (GWAS)
GWAS have a case-control or case-only design with disease status or a quantitative trait (for example, blood pressure) as the outcome. Typically, hundreds of thousands of common variants are genotyped simultaneously, and the frequencies of variants are compared between cases and controls or correlated with the trait of interest. GWAS are well suited to identifying common variants that increase risk of a disease but are not necessarily causative.
Penetrance
The conditional probability of a phenotype, such as amyotrophic lateral sclerosis, being associated with a given genotype.
C21orf2 is a poorly characterized protein, but is known to be crucial for DNA repair via an interaction with the serine/threonine protein kinase Nek1 (REF. 66 ). Nek1 also interacts with other proteins involved in neuron degeneration, including alsin and vesicle-associated membrane protein-associated protein B/C (VAPB). Both Nek1 and the C21orf2 protein are part of the ciliary proteome, or ciliome, and are required for the formation and maintenance of primary cilia 67 . Defects in primary cilia are associated with various neurological disorders, and the number of cilia is abnormally low in SOD1 G93A transgenic mice 68 . Microtubule organization and kinesin-dynein intraflagellar transport are essential for the maintenance of cilia structure and function; studies have shown that disruption of the microtubule cytoskeleton is associated with the development of ALS 69 , and that mutations of the dynein subunit dynactin are a rare cause of familial ALS 70 . Other cytoskeletal proteins implicated in ALS by genetics include VAPB, transitional endoplasmic reticulum ATPase (encoded by VCP), sec1 family domain-containing protein 1, optineurin (encoded by OPTN), profilin-1, neurofilament heavy polypeptide, and tubulin α-4A chain.
Several genes that code for proteins involved in RNA processing have been associated with ALS, albeit with varying levels of support 18,22,49,71-74 . Such genes include TAR DNA-binding protein 34 (TARDBP), fused in sarcoma (FUS), SETX, ELP3, angiogenin (ANG) and TAF15. RNA processing is a ubiquitous process, and why defects in these genes might result in specific injury to motor neurons is not yet clear.
As described above, the molecular pathways relevant to the development of ALS are involved in a host of processes, including DNA repair, RNA processing, autophagy, inflammation, protein degradation, mitochondrial dysfunction and cytoskeletal organization (see Supplementary information S1 (table)). These pathways are all logical therapeutic targets, but the implications of specific mutations for individual patients might be difficult to predict. However, progress in the discovery of novel ALS-related genes is accelerating (FIG. 2) , and biological insights will grow concomitantly, thereby fuelling novel therapeutic developments. Also, these biological discoveries are paving the way for precision medicine in ALS through the precise knockdown or even gene editing of specific ALS-associated mutations
Genetic counselling in ALS Oligogenic inheritance, pleiotropy and age-dependent penetrance are three genetic effects that compound the difficulty of interpreting newly identified mutations. Each of these effects has implications for counselling of patients with genetic risk variants and their family members.
Oligogenic inheritance.
Oligogenic inheritance refers to a situation in which a single mutation is not sufficient to cause disease despite significantly increasing risk, and other risk gene variants are required for the development of ALS. Oligogenic inheritance in ALS was first described in 2001 in a French family in which individuals with ALS had two different mutations: one in the maternal copy of the SOD1 gene, and the other in the Box 2 | Genome-wide next-generation sequencing studies Genome-wide association studies (GWAS) only capture common genetic variation, whereas whole-genome sequencing studies typically capture common and rare genetic variation. Next-generation sequencing studies use highly parallel DNA sequencing technologies that produce hundreds of thousands or millions of short reads of DNA (25-500 bp) at a low cost in a short time. The reads are then assembled into a full genome by a supercomputer. Rare variants can be so infrequent that statistical tests are not reliable, so special techniques are needed to identify association with disease. One method, an example of which is the cohort allelic sums test (CAST), compares the total extent of rare variation in a specific gene among patients and controls. Some tests -for example, the combined multivariate and collapsing method (CMC), or the weighted sums test (WST) -are weighted to account for the fact that large genes have more chance to accumulate rare variation. Another method tests each variant for association with disease independently, then combines the results across multiple DNA sequences to identify disease-associated genes. This strategy allows for the fact that some variants might be protective and cancel out risk variants. Examples of such tests are the sequence kernel association test (SKAT), the C-alpha test, and the estimated regression coefficient (EREC) test.
These tests can only assess gene variations in aggregate and, thus, do not aid interpretation of the pathogenicity of any specific variant. Instead, they provide evidence of whether the gene under investigation can be implicated in the disease being studied. Nature Reviews | Neurology paternal copy 75 . Over the past 4 years, more reports have described patients with oligogenic inheritance of ALS owing to combinations of risk variants in FUS, TARDBP, C9orf72, SOD1, VAPB, OPTN1 and ANG [76] [77] [78] . C9orf72 hexanucleotide repeat expansion confers a moderate risk for the development of ALS: not as large as for other familial disease genes, but far greater than the modest odds ratios seen for common variants associated with ALS. If oligogenic inheritance is a frequent theme in ALS, all relevant gene variants would need to be identified and tracked through a family to reveal the risk of ALS. The need to approach the assessment of risk in this manner would greatly complicate the interpretation of a positive gene test by genetic counsellors. The finding that knockdown of the transcription elongation factor SPT4 (SUPT4H1) gene in animal models and human cells derived from patients with ALS greatly reduces expression of the C9orf72 hexanucleotide repeat expansion 79 further exemplifies how oligogenic inheritance might affect genetic counselling: deletions or loss-of-function mutations in SUPT4H1 might be natural modifiers of C9orf72-mediated toxicity in humans, so an understanding of the variants in SUPT4H1 that each patient carries would be essential for interpreting the effects of a C9orf72 hexanucleotide expansion.
Pleiotropy.
Pleiotropy is the ability of mutations in a particular gene to result in different diseases, either simultaneously or in different individuals. For example, the hexanucleotide repeat expansion in C9orf72 can result in ALS, FTD or both 25 (FIG. 3) . For ATXN2, the situation is complicated further because the influence on disease depends on the exact variation: people with up to 28 CAG trinucleotide repeats are healthy, those with 29-32 repeats are at risk of ALS, and those with 33 or more repeats are at risk of spinocerebellar ataxia, with little overlap at the boundaries 48 . The repeat sizes are not stable between generations.
Pleiotropy in ALS is increasingly recognized, and is most frequently associated with FTD, but has also been linked to ataxia, parkinsonism, mitochondrial myopathies, Paget disease, Alzheimer-type dementia, psychiatric disorders such as schizophrenia and, possibly, multiple sclerosis. The variants that are associated with pleiotropy are found in a number of genes, including C9orf72, ATXN2, TBK1, FUS, C21orf2, NEK1, MATR3, CHCHD10, VCP, hnRNPA1 and hnRN-PA2B1 (REFS 10, 16, 26, 27 ) (see Supplementary information S1 (table) ). Pleiotropy has implications for genetic counselling in ALS, as the associated diseases are not always correctly recognized as a positive family history. Furthermore, the interpretation of a positive gene test for other family members is no longer limited to the risk of developing a single condition.
Age-dependent penetrance. Age-dependent penetrance is the probability of an individual developing a disease at any particular age, if they are a carrier of a mutation that is associated with increased risk. All ALS-associated genes and many genes associated with related conditions show age-dependent penetrance, with the risk of disease manifestation increasing with age. Age-dependent penetrance should be considered when counselling patients, because the identification of a risk variant for ALS does not necessarily mean that development of the disease is inevitable -the time needed for the disease to manifest might be greater than the lifespan of the individual. From a clinical perspective, this phenomenon can lead to the disease skipping generations and, therefore, affects the likelihood of a positive family history. The reduced risk of developing a disease must be explained to gene carriers and those at risk of carrying a disease gene, even though the exact profile of risk reduction is complex or unknown. Age-dependent penetrance also raises ethical difficulties; for example, prenatal screening could raise the question of whether to terminate a pregnancy if a fetus is identified as carrying a C9orf72 repeat expansion. The consequences of age-dependent penetrance are complex, and counselling should be provided by trained clinical geneticists 80 .
C9orf72 -a counselling case study. The complexity of genetic counselling in ALS is perhaps best illustrated by considering the hexanucleotide repeat expansion mutation of C9orf72. This mutation is carried by up to 10% of all people with ALS in some populations, regardless of family history 81 . Whether to test everyone with ALS -even those with apparently sporadic ALSis, therefore, a dilemma. On the one hand, a negative family history of ALS is not strong evidence against 
Amyotrophic lateral sclerosis risk genes
The identification of amyotrophic lateral sclerosis (ALS) risk genes that act in specific molecular pathways could allow a stratified treatment approach using compounds that target the pathway. ALS-associated genes do not all act through the same mechanism, and it is highly plausible that different compounds will be needed, depending on the class of genes involved in a subgroup of patients.
Specific mutations
The identification of specific mutations that act through a toxic gain-of-function mechanism in ALS may offer an opportunity for more-specific precision medicine. The most notable examples are the superoxide dismutase 1 (SOD1) and C9orf72 genes. The first steps towards this approach in ALS have already been taken, as a successful phase I study with SOD1 antisense therapy has already been performed, and a phase II/III trial is under way 90 . Also, many research groups are working on the development of gene-targeted therapies through the use of antisense oligonucleotides, and viral delivery of small interfering RNA, in particular for the C9orf72 mutation. One caveat is that overall knockdown of ALS-associated gene expression might also have detrimental effects, as seems to be the case for C9orf72 (REFS 91, 92) .
Precision medicine
The ultimate form of precision medicine, but one that is far from being readily available, is genome editing. Recent exciting breakthroughs in molecular biology have made it possible to induce or repair mutations through CRISPR-Cas9, a biological machinery originally discovered in bacteria (REFS 93, 94) . This form of 'pinpoint medicine' means that within one ALS-associated gene, every damaging mutation would need its own specific treatment.
High-throughput screening
Although gene variations can have robust statistical association with ALS, for many variants direct pathogenicity has not been demonstrated. High-throughput screening in neuronal cell models based on patient-derived induced pluripotent stem cells will make this process easier, but these functional assays should be performed only when the genetic evidence is sound 95 .
El Escorial criteria
Research criteria used to define the certainty that the phenotype will ultimately be amyotrophic lateral sclerosis rather than some other variant of motor neuron disease. The criteria are based on the distribution and pattern of upper and lower motor neuron signs, and have recently been revised to incorporate neurophysiological findings.
this single-gene cause. On the other hand, the correct interpretation of a positive result is not clear, as confirmation of the mutation in a family does not mean that the development of ALS in relatives is inevitable. Furthermore, no treatment is currently possible, although this situation could change as genetic therapies become available. The correct approach to these scenarios is still under debate, and regional differences exist: in some countries, health-care professionals only screen patients with ALS if there is a family history of ALS in a first-degree relative.
Multistep model. Oligogenic inheritance, pleiotropy and age-dependent penetrance can be explained by a multistep model of ALS pathogenesis, which has been shown to fit the incidence profile of the disease 82 . The evidence fits a model in which ALS results from, on average, six pathological steps, which might themselves be caused by one or more genetic or environmental risk factors. The disproportionately large role for low-frequency, high-risk variants in the genetic architecture of ALS, as opposed to the concerted action of thousands of lowrisk variants, is also consistent with this model. The multistep model also explains the gene-environment interaction, as some of the steps would be triggered by genes and others by environmental factors; however, an environmental trigger is only relevant within the context of a genetic trigger, because the interactions occur within a specific pathway.
Diagnosis and prognosis
In an ideal scenario, the gene profile of a patient with ALS would provide a sensitive and specific diagnostic test for ALS. Indeed, it has been proposed that the El Escorial criteria should have provision for diagnosis of ALS based on identification of a mutation in a familial ALS-associated gene 83 . However, this approach presents challenges for most patients with ALS because of the difficulties in interpreting a mutation when the patient has no family history. Nevertheless, a gene profile could still be useful for classification of ALS into subtypes that are amenable to specific treatment strategies, such as gene therapy or targeting of a disease pathway.
Many genes have been associated with ALS, and have the potential to aid interpretation of genetic test results and genetic counselling (see Supplementary information S1 (table) ). Genic constraint is the ability of a protein to functionally tolerate genetic variants in its coding gene; the most suitable genes for routine testing in an affected individual are those that are highly constrained 60 . If a mutation in a known risk gene is identified, even previously unknown mutations that lead to a truncated or absent protein could be regarded as pathogenic by the treating physician. Genes that are classified as having low interpretability for genetic counselling typically have mutations that change amino acids (see Supplementary information S1 (table)). These types of mutations are probably pathogenic, but the frequency of such mutations in the general population, and the lack of evidence that these genetic variants segregate with disease within a family, suggests that this is not always the case. Clinicians should be aware of this caveat if they routinely test patients for these genes. Routine testing should be avoided for genes in the 'variants of uncertain significance' category, as they encode proteins that are considered to be highly tolerant of amino acid changes.
Risk profiling of healthy individuals can be conducted with established methods to evaluate the total genetic risk 84 . However, use of individual gene profiles to predict the development of ALS is not -and is never likely to be -practical. An unavoidable problem with this approach is the risk of false-positive tests in rare conditions. Even in ideal circumstances, screening is likely to do more harm than good because the inevitable high false-positive rate leads to distress and unnecessary medical investigation.
Genetic studies do have a role in prognosis. At present, prediction is restricted to basic observations, such as aggressive or slowly progressive disease being associated with certain mutations of SOD1, or an increased risk of FTD in people with the C9orf72 expansion mutation 24, 46, [85] [86] [87] . Association studies that examine survival, however, offer the opportunity to generate a prognostic genetic score that could be used to stratify patients in clinical trials or, in combination with clinical features, to inform clinical care. An association between variants in UNC13A and a worse prognosis has already been replicated, and one study has indicated an association between variants in calmodulin-binding transcription activator 1 (CAMTA1) and a worse prognosis 88 .
Nature Reviews | Neurology Such findings are potentially important therapeutically, as the mechanisms of ALS progression could differ from the mechanisms of pathogenesis.
Conclusions
Genetic studies of ALS are at an exciting and crucial phase, with advances in technology and unprecedented large-scale international collaborations combining to rapidly escalate our understanding of the causes of this disease. As we increase our knowledge of the genes implicated in ALS and the range of clinical manifestations that can result, interpretation of the results of genetic testing may become easier, irrespective of the presence of a family history of ALS. The next advances are likely to include the development of personalized genetic profiles, which can be combined with other related information such as epigenetic test results. This knowledge will be used to generate person-specific treatments and lifestyle advice, designed to slow ALS progression on the basis of the specific genetic variation found in an individual, and will bring true precision medicine to ALS. 
